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1. Introduction 
The ductus arteriosus (DA), a fetal arterial shunt between the main pulmonary artery and the 
descending aorta, is a normal and essential fetal structure. Normally, the DA begins to close 
immediately after birth, but in some cases it remains patent after birth. Postnatal patent DA 
(PDA) is a major cause of morbidity and mortality in premature infants, leading to severe 
complications including pulmonary hypertension, right ventricular dysfunction, postnatal 
infections, and respiratory failure (Hermes-DeSantis & Clyman, 2006). The incidence of PDA 
among full-term newborns has been estimated at one in 500, and in preterm newborns it 
accounts for the majority of all congenital heart disease cases (Mitchell, 1971). The incidence of 
PDA exceeds 30% in preterm babies with birth weights <1,500 g (Van Overmeire, 2004). 
Curiously, patent DA can be essential for patients with complex congenital heart diseases in 
which the systemic or pulmonary circulation is dependent on the passage of blood through the 
DA. Therefore, a thorough understanding of the precise molecular mechanism underlying DA 
closure is very important in pediatric cardiovascular medicine. 
Closure of the human DA occurs in two phases: functional closure of the lumen within the 
first hours after birth by smooth muscle constriction, and anatomic occlusion of the lumen 
over the next several days due to extensive neointimal thickening and vascular remodelling. 
Although this overall process is similar among all mammals, the time course of the two 
phases varies among species.  
DA constriction after birth is induced by an increase in arterial oxygen tension, a dramatic 
decline in circulating prostaglandinE2 (PGE2), and a decrease in blood pressure within the 
DA lumen (Smith 1998; Clyman 2006). Anatomical closure of the DA is associated with a 
unique system of differentiation of the vessel wall. The most prominent phenotypic change 
is intimal thickening, a process characterized by (a) an area of subendothelial deposition of 
extracellular matrix, (b) the disassembly of the internal elastic lamina and loss of elastic fiber 
in the medial layer, and (c) the migration of undifferentiated medial smooth muscle cells 
(SMCs) into the subendothelial space. The DA later undergoes permanent closure through 
structural remodelling and fibrosis. The resulting fibrous band with no lumen persists in the 
adult as the ligamentum arteriosum (Fay & Cooke 1972). The cascade of events is thought to 
orchestrate the activation of subsequent signalling pathways, leading finally to the complete 
obliteration of the DA. In this chapter, we focus on reviewing the current state of knowledge 
regarding the mechanisms by which vascular remodelling of the DA is regulated. 
www.intechopen.com
 
Congenital Heart Disease – Selected Aspects 
 
86
2. Anatomical closure of the DA 
After birth, extensive remodelling of the DA wall occurs, leading to permanent closure of 
the DA. Although these rapid changes are readily apparent after birth, the structural 
remodelling of the DA has already begun in late gestation, under the control of the 
abovementioned unique differentiation system. Therefore, the DA has a distinct structural 
character from its neighboring arteries. For example, smooth muscle myosin isoform SM2, 
which is predominantly expressed in adult arteries, is highly expressed in the fetal DA (Kim, 
1993).  
2.1 Physiological intimal thickening of the DA 
Intimal thickening, though often observed in pathological arteries, such as injured or 
atherosclerotic arteries, is also a characteristic developmental structural change in the DA. 
The intimal thickening that occurs in the DA is physiological in nature and is required for 
postnatal DA closure (Rabinovitch, 1996; Yokoyama. 2006a). In rats, intimal thickening can 
be observed in the mature DA on the 21st day of gestation, though it is not observed in the 
immature DA on the 19th day of gestation. Intimal thickening starts with a lifting of the 
endothelial cells. Accumulations of hyaluronan and other extracellular matrices in the 
subendothelial region and fragmention of the inner elastic lamina provide optimal 
conditions for the migration of SMCs into the subendothelial region (De Reeder, 1988). 
These changes in DA structure have been well investigated both in rodents and in humans. 
Given that intimal thickening is poorly developed in patients with PDA and in animal 
models of PDA (Gittenberger-de Groot, 1980; Gittenberger-de Groot,1985; Tada,1985), this 
process must play a critical role in permanent closure of the DA after birth. Therefore, a 
common molecular mechanism must underlie the development of intimal thickening of the 
DA in humans and animals alike. 
2.2 Molecular mechanisms underlying intimal thickening 
Intimal thickening is associated with many characteristic phenomena such as the proliferation 
and migration of SMCs, the accumulation of extracellular matrix in the subendothelial region, 
and the fragmention of the inner elastic lamina. Analysis of the causal genes of this complex 
process in patients with PDA and animal models of PDA is resulting in significant progress 
toward understanding the molecular mechanism underlying it.  
2.2.1 Cyclooxygenase (COX): The generator of PGE2  
The cyclooxygenases COX1 and COX2 catalyze the synthesis of prostaglandin H, a 
precursor of biologically active prostaglandins including PGE2, from arachidonic acid. 
Therefore COX inhibitors such as indomethacin are often used for treatment of PDA to 
induce vasoconstriction of the DA by attenuating the synthesis of PGE2. Exposure in utero to 
indomethacin induces premature closure of the DA. Interestingly, it has been reported that 
infants of mothers who received indomethacin tocolysis are susceptible to symptomatic 
PDA. These contradictory observations suggest that a relatively complex mechanism 
underlies the role of COX1 and COX2 in the DA. Furthermore, genetic disruption of COX1 
and COX2 results in postnatal PDA (Loftin, 2001). As seen in COX-deleted mice, COX2 
plays a primary role in DA closure after birth, and its effect is attenuated in cases of preterm 
gestation. In addition to COX2, COX1 also contributes to DA closure in a gene dosage-
dependent manner (Loftin, 2001; Loftin, 2002). Although it is not apparent from the 
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literature why COX deletion causes PDA in mice, we assume that the same mechanism 
should work as described below in mice harboring deletion of the EP4 gene, a predominant 
PGE2 receptor in the DA. Trivedi et al. have demonstrated that COX2 expression is 
attenuated in EP4-deleted mice (Trivedi,. 2006), suggesting the existence of a positive 
feedback loop in COX-PGE2 cascades. 
2.2.2 Prostacyclin (PGI2) 
Dogs have been studied as an animal model of inherited PDA because their histological 
features of normal DA and PDA closely resemble those of humans. Through such studies, 
De Reeder et al. have demonstrated that the expression of PGI2 synthase is high in the 
endothelium and low in vascular SMCs in PDA and other patent neighboring arteries. In 
normally closing DA, in contrast, high amounts of PGI2 are found in the vascular SMCs of 
the intimal cushions, suggesting that PGI2 plays a role in the onset of intimal thickening (de 
Reeder, 1989).  
2.2.3 PGE2 – EP4: A critical player in regulating intimal thickening 
PGE2, the most potent vasodilator affecting the DA, is produced in the placenta (Smith 1998) 
and in the DA itself (Clyman, 1978; Coceani, 1978). During gestation, PGE2 contributes to 
DA patency in utero. Stimulation of PGE2 receptors activates adenylyl cyclases (ACs). The 
resulting increased intracellular concentrations of cyclic AMP (cAMP) inhibit myosin light 
chain kinase, inducing DA relaxation (Smith 1998). The dilator effect of PGE2 on the 
mammalian DA is mediated mainly by the PGE2 receptor, EP4. After birth, the concentration 
of circulating PGE2 declines dramatically as the placenta is removed and PGE2 is rapidly 
catabolised through lung circulation. Furthermore, the expression levels of PGE2 receptors 
are decreased in the DA wall (Smith 1998).  
Although PGE2 plays a primary role in maintaining the patency of the DA, previous studies 
have demonstrated that genetic disruption of EP4 paradoxically results in fatal PDA in mice 
(Nguyen, 1997; Segi, 1998). We have found that intimal thickening was completely absent in 
DA from EP4-disrupted neonatal mice (Yokoyama, 2006a). Moreover, a marked reduction in 
hyaluronan production was found in EP4-disrupted DA, whereas a thick layer of 
hyaluronan deposit was present in wild-type DA. PGE2-EP4-cAMP-protein kinase A (PKA) 
signalling up-regulates hyaluronan synthase type 2 mRNA, which increases hyaluronan 
production in the DA. Accumulation of hyaluronan then promotes SMCs migration into the 
subendothelial layer to induce intimal thickening (Yokoyama, 2006a). Therefore, signalling 
through PGE2-EP4 plays two essential roles in DA development, namely, vascular dilation 
and intimal thickening. 
2.2.4 Specific adenylyl cyclases regulate intimal thickening of the DA 
Chronic PGE2-EP4-AC-cAMP-PKA signalling during gestation induces vascular remodelling 
of the DA and thereby promotes hyaluronan-mediated intimal thickening and structural 
closure of the vascular lumen. Both PGE1 and PGE2 also induce vasodilation in the DA. Since 
intracellular cAMP is synthesized by ACs, which are transmembrane enzymes activated by G 
protein-coupled receptors, including PGE receptors, ACs must play an important role in 
regulating vasodilation and remodelling in the DA. To date, nine different isoforms of 
membrane-bound forms of ACs (AC1 through AC9) have been identified in vertebrate tissues. 
Most tissues express several AC isoforms, which exhibit remarkable diversity in their 
biochemical properties (Sunahara & Taussig 2002). Since SMCs in the DA exhibit biological 
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properties distinct from those of SMCs in other vessels such as the aorta, it is possible to 
identify specific AC isoforms that play a distinct role in the DA. Recent advances concerning 
AC isoform-selective activation or inhibition have allowed us to investigate the role of AC 
isoforms and the availability of AC isoform-selective activators in regulating DA vascular tone 
and remodelling. AC2 and AC6, for example, are more highly expressed in rat DA than in the 
aorta during the perinatal period (Yokoyama, 2010). AC6-targeted siRNA counteracts PGE-
induced hyaluronan production in rat DA SMCs. Overexpression of AC6 enhances PGE-
induced hyaluronan production and induces intimal thickening in DA explants. Furthermore, 
intimal thickening of the DA is less marked in mice lacking AC6 than in wild-type mice. 
Interestingly, stimulation of AC2 attenuates AC6-induced hyaluronan production via 
inhibition of the p38 mitogen-activated protein kinase pathway and AC6-induced intimal 
thickening of the DA. The AC2/6 activator 6-[N-(2-isothiocyanatoethyl) aminocarbonyl] 
forskolin (FD1) does not induce hyaluronan-mediated intimal thickening in DA explants, 
though the AC5/6 activator 6-[3-(dimethylamino)propionyl]-14 15-dihydroforskolin (FD6) 
does. Therefore AC6 must be responsible for hyaluronan-mediated intimal thickening of the 
DA, while AC2 inhibits AC6-induced hyaluronan production. It should be noted that the DA 
is dilated by stimulation with both FD1 and FD6, the effect of which is longer than that of 
stimulation with PGE1 (Yokoyama, 2010). These data suggest that the activation of both AC2 
and AC6 induces vasodilation, although the effectiveness of AC2 and AC6 activation has not 
yet been directly investigated. Administration of FD1 induces vasodilation without intimal 
thickening of the DA, suggesting that combinative stimulation with AC2 and AC6 or AC2-
specific stimulation may be a novel alternative therapy to current PGE therapy for patients 
with DA-dependent congenital heart disease. 
2.2.5 Epac (Exchange Protein Activated by cAMP): A novel target of cAMP 
A new target of cAMP, i.e., a new exchange protein activated by cAMP, has recently been 
discovered and is called Epac. Epac has been known to utilize a distinct cAMP signalling 
pathway that is independent of PKA (Bos 2006). Epac is a guanine nucleotide exchange protein 
that regulates the activity of small G proteins. There are two variants: Epac1 is expressed in 
most tissues, including the heart and blood vessels, whereas Epac2 is expressed in the adrenal 
gland and the brain. Although both Epac1 and Epac2 are up-regulated during the perinatal 
period, Epac1, but not Epac2, acutely promotes SMC migration and thus intimal thickening in 
the DA (Yokoyama, 2008). Since Epac stimulation does not increase hyaluronan production, 
the effect of Epac1 on SMC migration is independent of that of hyaluronan accumulation, 
which operates through a mechanism different from that underlying PKA stimulation. Epac 
stimulation improves the organization of actin stress fibers and enhances focal adhesion of DA 
SMCs. Therefore, the EP4-cAMP signal pathway can induce intimal thickening in the DA via a 
PKA-dependent mechanism or an Epac-dependent mechanism.  
2.2.6 Oxygen and reactive oxygen species 
The DA is an oxygen-sensitive tissue, and oxygen is its most potent vasoconstrictor. The DA 
senses the change in oxygen tension through the change in redox status. Redox and reactive 
oxygen species are known to play an important role in vascular remodelling of pathological 
arteries. Therefore, the change in oxygen tension that occurs after birth should affect 
postnatal vascular remodelling of the DA. In this regard, Clyman’s group has demonstrated 
that muscular constriction produces a region of ischemic hypoxia in the middle of the 
ductus muscle media and that intense hypoxia within the constricted vessel wall of the DA 
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induces vascular endothelial cell growth factor (VEGF), which in turn stimulates neointimal 
proliferation and vasa vasorum ingrowth (Waleh, 2010; Clyman, 2002). They have also 
emphasized that hypoxia in the vessel wall plays a role in permanent DA closure. Yet before 
the blood flow through the DA is completely obstructed, the DA is exposed to blood 
containing higher oxygen content after birth compared to the blood passing through it 
during the fetal period. Recently we have found that oxygenation promotes migration of DA 
SMCs followed by intimal thickening of the rat DA (unpublished data). Accordingly, 
oxygenation, in addition to inducing contraction, plays an important role in completing DA 
closure through promoting intimal thickening after PGE2 removal. Further investigation is 
warranted to elucidate the molecular mechanism by which oxygenation promotes intimal 
thickening of the DA.  
2.2.7 Calcium channel 
A growing body of evidence has demonstrated that voltage-dependent calcium channels 
(VDCCs), in addition to their role in determining the contractile state, play an important role 
in regulating differentiation, proliferation, migration, and gene expression in vascular 
SMCs. VDCCs are classified according to their distinct electrophysiological and 
pharmacological properties into low-voltage-activated (T-type) and high-voltage-activated 
(L-, N-, P-, Q-, and R-type) VDCCs. VDCCs consist of different combinations of ┙1 subunits 
and auxiliary subunits. Among the ┙1 subunits, ┙1C and ┙1G are the most predominant 
isoforms in the rat DA (Yokoyama, 2006b). In addition to a conventional ┙1C subunit, a 
novel alternatively spliced variant of the ┙1C isoform is highly expressed in the neointimal 
cushion of the rat DA, although the role of the spliced variant of the ┙1C isoform in 
neointimal cushion formation has not yet been investigated (Yokoyama, 2006b). 
Interestingly, ┙1G, a T-type VDCC, is significantly up-regulated in oxygenated rat DA tissue 
and in the region of intimal thickening in the DA (Akaike, 2009). ┙1G plays a role in 
migration of DA SMCs and neointimal cushion formation. R(-)-efonidipine, a T-type VDCC-
specific antagonist, delays the closure of the rat DA through inhibiting the contraction and 
neointimal formation of the DA (Akaike, 2009). Therefore, isoform-specific inhibition of 
VCDD may be an alternative therapeutic strategy to regulate the patency of the DA. 
2.2.8 Cytokines 
Inflammatory responses to vascular injury or atherosclerosis are known to be associated 
with the pathogenesis of neointimal thickening. Given that several proinflammatory 
cytokines are known to play an essential role during vascular remodelling, it is reasonable 
to assume that cytokines might contribute to physiological vascular remodelling processes 
as well, in particular, the permanent closure of the DA. Accordingly, it is likely that VEGF 
stimulates neointimal proliferation and vasa vasorum ingrowth during permanent DA 
closure, as described above (Waleh, 2010; Clyman, 2002). In addition, transforming growth 
factor-beta (TGF-┚) 1 in endothelial cells and SMCs probably regulates vascular remodelling 
of the DA, though the function and expression of TGF-┚ 1 in the DA are controversial 
(Tannenbaum, 1996; Zhou, 1998).  
Clyman’s group has demonstrated that the expression levels of vascular cell adhesion 
molecule (VCAM)-1 (an important ligand for the mononuclear cell adhesion receptor 
VLA4), E-selectin, IL-8, macrophage colony stimulating factor-1, CD154, interferon-gamma, 
IL-6, and tumor necrosis factor-alpha are increased in the ductus wall. They have also found 
that VLA4+ monocytes/macrophages (CD68+ and CD14+) and, to a lesser extent, T-
lymphocytes adhere to the postnatal DA (Waleh, 2005).  
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The expression of IL-15 mRNA is significantly higher in rat DA than in the aorta. IL-15 
immunoreactivity is detected predominantly in the internal elastic laminae, and to a lesser 
extent in SMCs, in the rat DA. IL-15 attenuates PDGF-BB-mediated SMC proliferation and 
PGE1-induced hyaluronan production in a dose-dependent manner. Accordingly, IL-15 
might have an inhibitory effect on the physiological vascular remodelling processes 
involved in closing the DA (Iwasaki, 2007). 
Moreover, growth hormones promote the migration of DA SMCs, thus enhancing intimal 
cushion formation in the DA. Growth hormones also regulate the expression of cytoskeletal, 
genes in DA SMCs, which may retain a synthetic phenotype in the smooth muscle-specific 
cytoskeletal genes (Jin, 2011).  
2.3 Vascular smooth muscle differentiation 
SMCs retain the ability to reversibly alter their phenotype in response to various 
environmental and physiological changes (McDonald and Owens 2007). This property has 
been termed phenotypic switching or SMC plasticity. Contractile SMCs express high levels 
of contractile proteins involved in establishing and maintaining myofilament structure and 
function, including SM22┙, SMA and SMMHC. In contrast, synthetic SMCs express lower 
levels of contractile muscle proteins and have higher rates of proliferation, migration and 
production of extracellular matrix components. The DA is a very specialized blood vessel, 
with a vascular wall composed of highly differentiated and contractile smooth muscle 
(Slomp, 1997). A unique transcriptional program is probably responsible for generating this 
particular artery during fetal development (Ivey, 2008). A growing body of evidence has 
demonstrated that maturation and differentiation of DA SMCs is essential for postnatal DA 
closure. Deletion of several factors that are required for DA SMCs to adopt a contractile 
phenotype results in PDA. It should be noted, however, that neointimal thickening is 
induced by migrating and proliferating vascular SMCs, which are characterized as a 
dedifferentiated (synthetic) phenotype. Therefore, the DA must consist of SMCs exhibiting 
phenotypic heterogeneity.  
2.3.1 Myocardin 
Myocardin is a remarkably potent transcriptional coactivator that regulates SMC contractile 
proteins. Myocardin-null mouse embryos exhibit a block in vascular SMC differentiation as 
well as defects in the yolk sac vasculature (Li, 2003). Importantly, mice generated after 
selective myocardin ablation of cardiac neural crest-derived vascular SMCs exhibit PDA and 
die at postnatal day 3 (Huang, 2008). In these mutant mice, the myocardin-deficient vascular 
SMCs populating the DA exhibit ultrastructural features generally associated with the 
synthetic, rather than the contractile, SMC phenotype. In addition, the architecture of the 
neointima and tunica media of the DA is markedly disturbed in association with a dramatic 
increase in extracellular matrix and a relative decrease in vascular SMC volume. These data 
demonstrate that myocardin regulates the expression of genes required to induce the 
contractile phenotype in neural crest–derived SMCs and provide new insights into the 
molecular and genetic systems that underlie the vascular remodeling of the DA. 
2.3.2 TFAP2B 
Identifying gene mutations in TFAP2B, a neural crest cell-specific transcription factor 
involved in Char syndrome, is one of the most important discoveries regarding the 
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molecular mechanism of PDA. Char syndrome is a genetic syndrome consisting of PDA in 
association with facial anomalies and minor skeletal anomalies (Chen, 2011; Satoda, 2000; 
Khetyar, 2008). In addition, Ivey et al. has demonstrated that TFAP2B disruption affects the 
development of vascular SMCs in the DA (Ivey, 2008), although they did not observe 
morphological differences between TFAP2B–/– and wild-type mice at embryonic days 13.5, 
15.5 and 18.5. It will be intriguing to examine in future studies whether TFAP2B plays a role 
in neointimal formation of the DA.  
2.3.3 Jag1 
The evolutionarily conserved Notch signaling pathway plays a major role in vascular 
development in mammals and other vertebrates (Kurpinski, 2010; High, 2008). Mice with 
SMC-specific deletion of Jag1, which encodes a Notch ligand, die postnatally from PDA 
(Feng, 2010). These mice exhibit defects in contractile SMC differentiation in the medial 
vascular wall of the DA, which therefore fails to express contractile SMC proteins. However, 
the differentiation of contractile vascular SMCs is confined to the region adjacent to the 
endothelial cell layer in the DA. Therefore, propagation of the Jag1-Notch signal throughout 
the width of the vascular wall is required for contractile SMC differentiation of the DA.  
2.4 Extracellular matrix involved in vascular remodelling of the DA 
Vascular cells are defined by the ways in which they regulate their extracellular matrix, and 
changes in the extracellular matrix, in turn, determine vascular cell phenotype, i.e. the 
ability to differentiate, proliferate, and migrate (Rabinovitch, 1996). As described in section 
2.2.3, PGE-induced hyarulonan plays a critical role in the onset of intimal thickening of the 
DA (De Reeder, 1988; Yokoyama, 2006a). In addition, it has been reported that DA SMCs 
produce twice as much fibronectin as aortic SMCs do (Rabinovitch, 1996). Mason et al. have 
demonstrated that preventing fibronectin-dependent intimal thickening would be a feasible 
manipulation to cause PDA as a mode of treatment of congenital heart diseases (Mason, 
1999). TGF ┚ and nitric oxide induce extracellular matrix, including hyaluronan and 
fibronectin, in DA SMCs (Rabinovitch, 1996). Future studies will be needed to determine the 
other constituents of extracellular matrix that play a role in vascular remodelling of the DA.  
2.5 Disassembly of the internal elastic lamina and loss of elastic fiber in the medial 
layer of the DA 
The disassembly and fragmentation of the internal elastic lamina and sparse elastic fibers in 
the middle layer of the DA is a hallmark of vascular remodelling in the DA. In the normally 
closing DA, impaired elastogenesis coincides with increased SMC migration and 
proliferation, contributing to physiological occlusion. The reduced elasticity of the DA wall 
may help its structure collapse easily as a prelude to postnatal permanent closure of the DA. 
In PDA, in contrast, an abundance of elastin lamellae in the intima, a subendothelial elastic 
lamina, and a failure of intimal SMC migration are found in humans and animal models (de 
Reeder, 1990; Hinek, 1991; Slomp, 1992). In humans and in animal models such as canine 
puppies and the inbred Brown-Norway (BN) rat (Bokenkamp, 2006), the subendothelial 
elastic lamina is thought to limit the passage of SMCs from the media to the intima. In PDA 
in BN rats, the media of elastin lamellae are absent, and the intima contains many elastic 
fibers. The abnormal distribution of elastin in the PDA of BN rats suggests that impaired 
elastin metabolism is related to the persistence of the DA and implicates a genetic factor that 
may link the PDA with aortic fragility. In this regard, recent studies have identified a new 
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aortic aneurysm syndrome that is due to mutations in the TGF ┚ receptors 1 and 2 and is 
associated with PDA and ductal aneurysm (Loeys, 2005). Further investigation is required to 
identify the molecular mechanism underlying the impaired elastogenesis in cases of DA.  
3. Conclusion 
Ductal closure occurs in two phases. In full-term newborns, the first few hours after birth 
see acute and functional closure as a result of smooth muscle contraction of the DA, which is 
triggered by an increase in oxygen tension and a decline in levels of circulating PGE2. 
Importantly, prior to this, anatomical vascular remodelling occurs under the control of 
highly conserved yet complex molecular mechanisms. This remodelling requires a specific 
sequence of processes, which includes the differentiation of vascular SMCs and endothelial 
cells, the accumulation of extracellular matrix, vascular SMC migration into the 
subendothelial region, impaired elastogenesis, and eventually fibrotic changes due to 
apoptosis and necrosis. Recent advances in high-throughput genetic screening for human 
diseases and genetically manipulated animal models of PDA have facilitated the 
identification of pathways and genes involved in development and closure of the DA. As 
seen in the PGE2-EP4-cAMP signal pathway as well as in the oxygen and calcium channels, 
multiple vasoreactive stimulations can serve as an important modulator of vascular 
remodelling of the DA. In this regard, endothelin-1, nitric oxide, and other vasoreactive 
factors in the DA that we have not discussed here in detail may play a role in vascular 
remodelling of the DA. Thus, it is reasonable to infer that endothelial cells in the DA may 
also play an important role in the differentiation of vascular SMCs, which are considered to 
be a pivotal cellular structure in the pathogenesis of PDA. In addition to its role in 
controlling vascular tone in the functional closure of the DA, the vascular remodelling of the 
DA is now attracting considerable attention as a target for novel therapeutic strategies for 
patients with PDA and DA-dependent cardiac anomalies. 
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